What is the official ID of this bill?

The official print number for this legislation is HR 8143.

When did the legislative process begin?

The process officially started on 2026-03-27.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/119/bills/hr8143/BILLS-119hr8143ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-04-13.

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-7].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Introduced in House

Analysis and Potential Impact of HR 8143

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026

Q: What are the main provisions?

Key points include: Mandatory inclusion of lower-cost generic and biosimilar drugs in preferred insurance tiers. Reduced out-of-pocket expenses for seniors enrolled in Medicare prescription drug plans. Prohibition of restrictive rules, like prior authorization, that make it harder to get cheaper drugs than brand-name ones. Requirement for plans to include at least two lower-cost biosimilar alternatives for biological products.

This bill requires Medicare Part D plans to prioritize cheaper generic and biosimilar drugs by placing them in tiers with lower out-of-pocket costs. It aims to reduce the financial burden on seniors and simplify access to affordable medication.

Key points

Mandatory inclusion of lower-cost generic and biosimilar drugs in preferred insurance tiers.

Reduced out-of-pocket expenses for seniors enrolled in Medicare prescription drug plans.

Prohibition of restrictive rules, like prior authorization, that make it harder to get cheaper drugs than brand-name ones.

Requirement for plans to include at least two lower-cost biosimilar alternatives for biological products.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Introduced

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.

Print number: HR 8143

Sponsor: Rep. Matsui, Doris O. [D-CA-7]

Process start date: 2026-03-27

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-flash-latest

Source data: api.congress.gov

AI work logs for this document launch